Cellerant lassos $36.4M in new BARDA funds for radiation drug
This article was originally published in Scrip
Executive Summary
California biotech Cellerant Therapeutics garnered $36.4 million under an option exercised by the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development of CLT-008, an investigational first-in-class, allogeneic, cell-based therapy, as a treatment for acute radiation syndrome (ARS).